| Pakuotė |
Reg. Nr. |
|
Kompensavimas i |
| MK |
BK |
Paciento priemoka |
| 100% |
90% |
80% |
50% |
|
Eosine Gifrer 2g/100ml cutaneous solution 100ml N1 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 45ml N16 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 100ml N30 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 10ml N8 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 2ml N16 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 5ml N20 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 45ml N32 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 2ml N10 |
98/6103/10
|
|
|
|
|
|
|
|
|
Eosine Gifrer 2g/100ml cutaneous solution 10ml N16 |
98/6103/10
|
|
|
|
|
|
|
|
2024 balandžio 26 d., penktadienis 
